Notice of Interim Results and Investor Presentation
News
Monday August 23, 2021
Notice of Interim Results and Investor Presentation
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Interim Results and Investor Presentation Brighton, United Kingdom – 23rd August 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage […]
Monday August 2, 2021
Secondary endpoint analysis from Phase 2b trial
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Update on secondary endpoint analysis from recent positive Phase 2b trial Cardiac surgery patients receiving XF-73 nasal gel exhibited a valuable, sustained […]